Cabanas, Helene, Muraki, Katsuhiko, Eaton-Fitch, Natalie et al. · Frontiers in immunology · 2021 · DOI
This study investigated whether a low-dose medication called naltrexone (LDN) might help treat ME/CFS by examining how it affects immune cells called NK cells. Researchers found that NK cells from ME/CFS patients taking LDN showed restored activity in a specific ion channel (TRPM3) that had previously been impaired. This suggests LDN may help restore normal immune function in ME/CFS patients, though larger clinical trials are needed to confirm whether it actually improves symptoms.
This study provides a potential mechanistic explanation for why some ME/CFS patients report symptom improvement with low-dose naltrexone, focusing on a specific immune pathway (TRPM3 in NK cells) that may be dysfunctional in ME/CFS. Understanding the underlying biology of how LDN might work could accelerate development of new treatments and support clinical trials. The work bridges patient-reported benefits with laboratory evidence, which is crucial for validating emerging therapies.
This study does not demonstrate that LDN actually improves ME/CFS symptoms in patients—it only shows that ion channel function is restored in laboratory conditions. The small sample size (9 patients) and lack of clinical outcome measures mean we cannot yet conclude LDN is an effective treatment. Additionally, restoration of ion channel activity in vitro does not necessarily translate to clinical benefit, and correlation between biomarker changes and symptom relief has not been established.
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Contribute
Private, reviewed by a human. Not a public comment thread.